NCT02123667 (ATLANTIS) is a clinical trial in Asthma, sponsored by Chiesi Farmaceutici S.p.A..

Who is sponsoring NCT02123667?

NCT02123667 is sponsored by Chiesi Farmaceutici S.p.A..

Is NCT02123667 still recruiting?

NCT02123667 is currently completed. Last updated 31 July 2020.

Last reviewed 2020-07-31 · How we verify

NCT02123667: ATLANTIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)

Completed Last updated 31 July 2020

What this trial tests

trial in Asthma in 872 participants. Completed in 4 March 2017.

Timeline

30 June 2014

Primary endpoint
4 March 2017

4 March 2017

Quick facts

Lead sponsor	Chiesi Farmaceutici S.p.A.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	872
Start date	30 June 2014
Primary completion	4 March 2017
Estimated completion	4 March 2017
Sites	26 locations across Italy, Netherlands, Germany, Canada, China, Spain, United States, Brazil

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Chiesi Farmaceutici S.p.A. — full company profile →

Who can join

Adults 18 to 65, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multinational, multicentre, non-pharmacological intervention, cross-sectional and longitudinal study.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study.
Postma DS, Brightling C, Baldi S, Van den Berge M, et al · · 2019 · cited 275× · PMID 30876830 · DOI 10.1016/s2213-2600(19)30049-9
Sex differences in asthma control, lung function and exacerbations: the ATLANTIS study.
Kole TM, Muiser S, Kraft M, Siddiqui S, et al · · 2024 · cited 9× · PMID 38901877 · DOI 10.1136/bmjresp-2024-002316
Neutrophilic inflammation in sputum or blood does not define a clinically distinct asthma phenotype in ATLANTIS.
Kuks PJM, Kole TM, Kraft M, Siddiqui S, et al · · 2025 · cited 2× · PMID 39963164 · DOI 10.1183/23120541.00616-2024
Assessment of the role of small airway dysfunction in relation to exacerbation risk in patients with well controlled asthma (ATLANTIS): an observational study.
Galant SP, Kuks PJM, Kole TM, Kraft M, et al · · 2025 · cited 1× · PMID 41038213 · DOI 10.1016/s2213-2600(25)00283-8
Small Airways Dysfunction and Remission in Adults With Asthma: A Longitudinal Exploratory Analysis of the AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) Study.
Kumar A, Chan R, Zounemat-Kermani N, Quek E, et al · · 2026 · PMID 41708533 · DOI 10.1111/all.70264
Cluster Analysis to Identify Distinct Asthma Phenotypes in the ATLANTIS Cohort.
Kuks PJM, Karp T, Hartman JE, Kraft M, et al · · 2026 · PMID 41212157 · DOI 10.1111/all.70127

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Chiesi Farmaceutici S.p.A. trials

Trials by the same sponsor.

NCT07516951 — A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis · Phase 2 · not yet recruiting
NCT07301736 — Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma · Phase 2 · recruiting
NCT07163182 — Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and · Phase 1 · recruiting
NCT06900816 — A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate C · Phase 2 · completed
NCT06892756 — Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02123667 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chiesi Farmaceutici S.p.A.
Last refreshed: 31 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02123667.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing